IL129877A - A pharmaceutical preparation containing a component having an Xa antagonist activity and an antifouling agent - Google Patents

A pharmaceutical preparation containing a component having an Xa antagonist activity and an antifouling agent

Info

Publication number
IL129877A
IL129877A IL12987797A IL12987797A IL129877A IL 129877 A IL129877 A IL 129877A IL 12987797 A IL12987797 A IL 12987797A IL 12987797 A IL12987797 A IL 12987797A IL 129877 A IL129877 A IL 129877A
Authority
IL
Israel
Prior art keywords
compound
platelet aggregation
activity
aggregation antagonist
antagonist compound
Prior art date
Application number
IL12987797A
Other languages
English (en)
Hebrew (he)
Other versions
IL129877A0 (en
Original Assignee
Aventis Pharm Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21861879&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL129877(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharm Prod Inc filed Critical Aventis Pharm Prod Inc
Publication of IL129877A0 publication Critical patent/IL129877A0/xx
Publication of IL129877A publication Critical patent/IL129877A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL12987797A 1996-11-27 1997-11-24 A pharmaceutical preparation containing a component having an Xa antagonist activity and an antifouling agent IL129877A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3187896P 1996-11-27 1996-11-27
PCT/US1997/021440 WO1998023279A1 (en) 1996-11-27 1997-11-24 PHARMACEUTICAL COMPOSITION COMPRISING A COMPOUND HAVING ANTI-Xa ACTIVITY AND A PLATELET AGGREGATION ANTAGONIST COMPOUND

Publications (2)

Publication Number Publication Date
IL129877A0 IL129877A0 (en) 2000-02-29
IL129877A true IL129877A (en) 2004-08-31

Family

ID=21861879

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12987797A IL129877A (en) 1996-11-27 1997-11-24 A pharmaceutical preparation containing a component having an Xa antagonist activity and an antifouling agent

Country Status (28)

Country Link
US (2) US6103705A (sk)
EP (1) EP0946185B2 (sk)
JP (1) JP4498471B2 (sk)
KR (1) KR100512671B1 (sk)
CN (1) CN1121224C (sk)
AP (1) AP1390A (sk)
AT (1) ATE283062T1 (sk)
AU (1) AU754936B2 (sk)
BG (1) BG64542B1 (sk)
BR (1) BR9713141A (sk)
CA (1) CA2272317C (sk)
CZ (1) CZ298552B6 (sk)
DE (1) DE69731763T3 (sk)
DK (1) DK0946185T4 (sk)
EA (1) EA002475B1 (sk)
ES (1) ES2230624T5 (sk)
HK (1) HK1023504A1 (sk)
HU (1) HUP9903496A3 (sk)
IL (1) IL129877A (sk)
NO (1) NO327740B1 (sk)
OA (1) OA11049A (sk)
PL (1) PL189116B1 (sk)
PT (1) PT946185E (sk)
SI (1) SI0946185T2 (sk)
SK (1) SK286024B6 (sk)
UA (1) UA63929C2 (sk)
WO (1) WO1998023279A1 (sk)
ZA (1) ZA9710691B (sk)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL129877A (en) * 1996-11-27 2004-08-31 Aventis Pharm Prod Inc A pharmaceutical preparation containing a component having an Xa antagonist activity and an antifouling agent
FR2764511B1 (fr) 1997-06-13 2000-09-08 Sanofi Sa Compositions pour le traitement et la prevention de la thrombose arterielle et utilisation d'un inhibiteur du facteur xa seul et/ou en combinaison avec un antiagregant plaquettaire
US6136794A (en) * 1998-02-02 2000-10-24 Merck & Co., Inc. Platelet aggregation inhibition using low molecular weight heparin in combination with a GP IIb/IIIa antagonist
WO2000029019A1 (en) * 1998-11-18 2000-05-25 G.D. Searle & Co. Restoration of platelet aggregation by antibody administration after gpiib/iiia antagonist treatment
MXPA02000142A (es) * 1999-06-30 2003-07-21 Hamilton Civic Hospitals Res Composiciones de heparina que inhiben los factores de coagulacion asociados con el coagulo.
ES2161615B1 (es) * 1999-07-23 2003-03-16 Rovi Lab Farmaceut Sa Composiciones de heparinas de muy bajo peso molecular.
US6969705B2 (en) * 2000-07-21 2005-11-29 Aventis Pharma S.A. Compositions of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them
JP2004507562A (ja) * 2000-09-08 2004-03-11 ハミルトン　シビック　ホスピタルズ　リサーチ　ディベロップメント　インコーポレイテッド 抗血栓性組成物
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
DE10141106A1 (de) * 2001-08-22 2003-03-13 Aventis Pharma Gmbh Verwendung von Heparinoid-Derivaten zur Behandlung und Diagnose von mit Heparinoiden behandelbaren Erkrankungen
US20040171819A1 (en) * 2002-10-10 2004-09-02 Aventis Pharma S.A. Mixtures of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them
ATE406364T1 (de) * 2003-03-07 2008-09-15 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
ES2318274T3 (es) 2003-03-07 2009-05-01 Schering Corporation Compuestos de azetidinona sustituida, formulaciones y uso de los mismos para el tratamiento de hipercolesterolemia.
US7956046B2 (en) * 2003-07-24 2011-06-07 Aventis Pharma S.A. Oligosaccharide mixtures derived from heparin, preparation thereof and pharmaceutical compositions containing them
EP1537871A1 (en) * 2003-12-04 2005-06-08 Aventis Pharma S.A. Enoxaparin for the treatment of cancer
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
KR100601429B1 (ko) * 2004-07-09 2006-07-14 주식회사 대우일렉트로닉스 기계식 전자렌지의 댐퍼 구동회로
AR067345A1 (es) * 2007-07-10 2009-10-07 Paion Deutschland Gmbh Uso de trombomodulina para la preparacion de un medicamento trombolitico
EP2014296A1 (en) * 2007-07-10 2009-01-14 PAION Deutschland GmbH Novel strategies for increasing the reperfusion in obstructed blood vessel
CN101783857B (zh) * 2009-05-12 2011-11-30 上海海事大学 一种基于fpga在高分辨率成像系统中的图像矩阵化预处理方法
IT1400232B1 (it) * 2010-05-07 2013-05-24 Advance Holdings Ltd Composizione farmaceutica topica comprendente eparina
WO2011149110A1 (en) 2010-05-28 2011-12-01 Daiichi Sankyo Company, Limited Novel composition for the prevention and/or treatment of thromboembolism
EP2508892A1 (de) * 2011-04-04 2012-10-10 Siemens Healthcare Diagnostics Products GmbH Kontrollen und Kit für Thrombozytenaktivitätsteste
RU2554803C1 (ru) * 2014-06-26 2015-06-27 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ профилактики развития послеоперационных венозных тромбоэмболических осложнений у пациентов с колоректальным раком

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3766167A (en) * 1971-03-26 1973-10-16 Research Corp Orally active anticoagulant
SE449753B (sv) * 1978-11-06 1987-05-18 Choay Sa Mukopolysackaridkomposition med reglerande verkan pa koagulation, lekemedel innehallande densamma samt forfarande for framstellning derav
FR2440376A1 (fr) * 1978-11-06 1980-05-30 Choay Sa Composition mucopolysaccharidique ayant une activite regulatrice de la coagulation, medicament la contenant et procede pour l'obtenir
US4692435A (en) * 1978-11-06 1987-09-08 Choay, S.A. Mucopolysaccharide composition having a regulatory action on coagulation, medicament containing same and process of preparation
FR2478646A2 (fr) * 1980-03-20 1981-09-25 Choay Sa Composition mucopolysaccharidique ayant une activite regulatrice de la coagulation, medicament la contenant et procede pour l'obtenir
CA1136620A (en) * 1979-01-08 1982-11-30 Ulf P.F. Lindahl Heparin fragments having selective anticoagulation activity
US4826827A (en) * 1979-10-05 1989-05-02 Choay S.A. Short chained oligosaccharides having biological properties, a process for making the same and the use thereof as drugs
FR2482611B1 (fr) * 1980-05-14 1986-03-07 Pharmindustrie Nouveaux polysaccharides sulfates, procedes pour leur preparation et leur utilisation comme medicaments
US4351938A (en) * 1980-05-19 1982-09-28 Riker Laboratories, Inc. Anticoagulant substance
FR2503714B1 (fr) * 1981-04-10 1986-11-21 Choay Sa Procede d'obtention de mucopolysaccharides biologiquement actifs, de purete elevee, par depolymerisation de l'heparine
EP0066908B1 (en) * 1981-05-21 1985-08-28 Akzo N.V. New anti-thromboticum based on polysacharides, method for its preparation and pharmaceutical compositions
US4533549A (en) * 1983-01-04 1985-08-06 Lasker Sigmund E Antithrombotic agent
IT1195497B (it) * 1983-03-08 1988-10-19 Opocrin Spa Procedimento per la preparazione di frazioni oligosaccaridiche dotate di proprieta' farmacologiche per degradazione chimica di eparina
US4683291A (en) * 1985-10-28 1987-07-28 Scripps Clinic And Research Foundation Platelet binding inhibitors
DK196986D0 (da) * 1986-04-30 1986-04-30 Novo Industri As Fremstilling af polysaccharider
DK196886D0 (da) * 1986-04-30 1986-04-30 Novo Industri As Fremstilling af polysaccharider
US4833155A (en) * 1986-11-25 1989-05-23 Syntex (U.S.A.) Inc. 3-(ω-(3,5,-di-t-butyl-4-hydroxyphenyl)-alkanoyl)pyrroles, and anti-inflammatory uses thereof
ES2052595T3 (es) * 1986-12-15 1994-07-16 Inst Nat Sante Rech Med Nuevos derivados peptidicos y su aplicacion en especial en terapeutica.
US4857508A (en) * 1987-12-03 1989-08-15 Monsanto Company Novel platelet-aggregation inhibitor peptide derivatives
KR940009084B1 (ko) * 1988-05-18 1994-09-29 체크 포인트 시스템스, 인코오퍼레이티드 자기 및 공명회로 검출용 안테나 시스템
IT1234508B (it) * 1988-06-10 1992-05-19 Alfa Wassermann Spa Derivati eparinici e procedimento per la loro preparazione
US5037808A (en) * 1988-07-20 1991-08-06 Monsanto Co. Indolyl platelet-aggregation inhibitors
US4879313A (en) * 1988-07-20 1989-11-07 Mosanto Company Novel platelet-aggregation inhibitors
US4992463A (en) * 1988-07-20 1991-02-12 Monsanto Company Thienyl peptide mimetic compounds which are useful in inhibiting platelet aggregation
IT1234826B (it) * 1989-01-30 1992-05-29 Alfa Wassermann Spa Derivati eparinici e procedimento per la loro preparazione
US5023233A (en) * 1989-07-28 1991-06-11 Merck & Co., Inc. Fibrinogen receptor antagonists
CA2066047A1 (en) * 1989-09-29 1991-03-30 Scott I. Klein Anti-thrombotic peptides and pseudopeptides
US4952562A (en) * 1989-09-29 1990-08-28 Rorer Pharmaceutical Corporation Anti-thrombotic peptides and pseudopeptides
US5051405A (en) * 1989-10-10 1991-09-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Anti-thrombotic peptides and pseudopeptides
US5053392A (en) * 1989-12-01 1991-10-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Novel arginine, glycine, aspartic acid derivatives as platelet-aggregation inhibitors
US5086069A (en) * 1990-02-05 1992-02-04 Rorer Pharmaceutical Corporation Anti-thrombotic peptide and pseudopeptide derivatives
US5064814A (en) * 1990-04-05 1991-11-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Anti-thrombotic peptide and pseudopeptide derivatives
NZ239876A (en) * 1990-09-27 1993-12-23 Merck & Co Inc Glycyl-b-alanine derivatives and pharmaceutical compositions thereof.
NZ239846A (en) * 1990-09-27 1994-11-25 Merck & Co Inc Sulphonamide derivatives and pharmaceutical compositions thereof
IL99539A0 (en) * 1990-09-27 1992-08-18 Merck & Co Inc Fibrinogen receptor antagonists and pharmaceutical compositions containing them
DE4290097T1 (sk) * 1991-01-24 1993-01-28 Aerojet-General Corp., Rancho Cordova, Calif., Us
AU668865B2 (en) * 1991-05-02 1996-05-23 Irun R. Cohen Compositions for the prevention and/or treatment of pathological processes
WO1993008845A1 (en) * 1991-11-08 1993-05-13 Massachusetts Institute Of Technology Localized oligonucleotide therapy
AU6415894A (en) * 1993-03-29 1994-10-24 Du Pont Merck Pharmaceutical Company, The Cyclic compounds useful as inhibitors of platelet glycoprotein iib/iiia
ATE199727T1 (de) * 1993-10-15 2001-03-15 Rhone Poulenc Rorer Pharma Antithrombotisch wirkende azacycloalkyl-alkanoyl- peptide und-pseudopeptide
US5639469A (en) * 1994-06-15 1997-06-17 Minnesota Mining And Manufacturing Company Transmucosal delivery system
US5763427A (en) * 1995-03-31 1998-06-09 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
US5721214A (en) * 1995-06-07 1998-02-24 Cor Therapeutics, Inc. Inhibitors of factor Xa
AU2202397A (en) * 1996-03-28 1997-10-17 G.D. Searle & Co. Iib/iiia antagonists co-administered with aspirin and/or heparin
IL129877A (en) * 1996-11-27 2004-08-31 Aventis Pharm Prod Inc A pharmaceutical preparation containing a component having an Xa antagonist activity and an antifouling agent

Also Published As

Publication number Publication date
WO1998023279A1 (en) 1998-06-04
US20020032214A1 (en) 2002-03-14
JP4498471B2 (ja) 2010-07-07
CZ298552B6 (cs) 2007-10-31
HUP9903496A2 (hu) 2000-10-28
DE69731763T3 (de) 2010-12-30
US6103705A (en) 2000-08-15
EP0946185A1 (en) 1999-10-06
CN1121224C (zh) 2003-09-17
KR100512671B1 (ko) 2005-09-07
HK1023504A1 (en) 2000-09-15
CN1238693A (zh) 1999-12-15
ES2230624T3 (es) 2005-05-01
EP0946185B1 (en) 2004-11-24
DE69731763D1 (de) 2004-12-30
PT946185E (pt) 2005-02-28
AP1390A (en) 2005-04-15
OA11049A (en) 2002-02-18
AU5454698A (en) 1998-06-22
DE69731763T2 (de) 2005-06-30
NO327740B1 (no) 2009-09-14
CA2272317C (en) 2001-01-30
DK0946185T4 (da) 2010-08-30
HUP9903496A3 (en) 2001-03-28
BG64542B1 (bg) 2005-07-29
KR20000057265A (ko) 2000-09-15
CZ174299A3 (cs) 1999-09-15
EA199900499A1 (ru) 2000-04-24
SK67399A3 (en) 2000-07-11
SI0946185T1 (en) 2005-06-30
ATE283062T1 (de) 2004-12-15
DK0946185T3 (da) 2005-03-21
PL189116B1 (pl) 2005-06-30
NO992555L (no) 1999-05-27
NO992555D0 (no) 1999-05-27
BR9713141A (pt) 2000-02-08
SI0946185T2 (sl) 2010-08-31
BG103372A (en) 2000-01-31
IL129877A0 (en) 2000-02-29
ES2230624T5 (es) 2010-10-25
ZA9710691B (en) 1998-06-12
EA002475B1 (ru) 2002-06-27
EP0946185A4 (en) 2001-06-27
AU754936B2 (en) 2002-11-28
JP2001506603A (ja) 2001-05-22
UA63929C2 (uk) 2004-02-16
AP9901517A0 (en) 1999-06-30
EP0946185B2 (en) 2010-05-05
SK286024B6 (sk) 2008-01-07

Similar Documents

Publication Publication Date Title
EP0946185B1 (en) PHARMACEUTICAL COMPOSITION COMPRISING A COMPOUND HAVING ANTI-Xa ACTIVITY AND A PLATELET AGGREGATION ANTAGONIST COMPOUND
Hanke et al. Inhibition of cellular proliferation after experimental balloon angioplasty by low-molecular-weight heparin.
JP2003526617A (ja) 種々の血栓塞栓性障害の予防および治療のための併用療法を提供する低分子量へパリンと血小板凝集阻害剤との相乗効果
CN102209546A (zh) 使用达比加群酯或其盐治疗或预防血栓形成且与常规的华法林疗法相比具有改良有效性的方法
US20200360280A1 (en) Unit Aerosol Doses For Anticoagulation
Buchanan et al. Prevention of thrombus formation and growth by antithrombin III and heparin cofactor II-dependent thrombin inhibitors: importance of heparin cofactor II
Rebello et al. Antithrombotic efficacy of a novel factor Xa inhibitor, FXV673, in a canine model of coronary artery thrombolysis
IML Queiroz et al. An evaluation of the efficacy of local hemostatic measures in dental patients taking oral anticoagulants: a critical review of the literature over the past two decades
JP3838680B2 (ja) 抗凝血物質に対する解毒剤として用いるのに適した医薬およびその使用
HU219595B (hu) Von Willebrand-faktort tartalmazó koncentrátumok alkalmazása trombózis elleni szerek és/vagy fibrinotikus szerek okozta vérzésnél antidotumként ható szer előállítására
MXPA99005008A (en) PHARMACEUTICAL COMPOSITION COMPRISING A COMPOUND HAVING ANTI-Xa ACTIVITY AND A PLATELET AGGREGATION ANTAGONIST COMPOUND
Rebello et al. Superiority of enoxaparin over heparin in combination with a GPIIb/IIIa receptor antagonist during coronary thrombolysis in dogs
Callas et al. Studies on the thrombogenic effects of recombinant tissue factor
Champion et al. The effects of four commonly used drugs on platelet function
Bunce et al. Platelet function in patients receiving enprostil
CN109939110A (zh) 药根碱在制备抗血栓药物中的应用
PIZZO et al. in Vivo Regulation of Thrombin Generation and Activitya

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees